Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
When it comes to expenses, CEFs are quite different than open-end mutual funds.
A look at ownership data can provide a more detailed look at what mutual funds and institutional players are buying and selling.
Despite the market's wild ride, most CEFs closed the year with positive share price and NAV returns.
Morningstar's Steve Pikelny discusses his closed-end fund ideas for international fixed-income and equity exposure and the advantages for using CEFs in these areas.
We saw some big trend reversals in 2012's fund launches.
Plus, Wasatch to launch India fund , and more.